Effect of high protein regime in nurocritical patients

Phase 3

Recruiting

Conditions: Diseases of the nervous system injury.
Diffuse traumatic brain injury

Registration Number: IRCT20120703010178N14

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 30

Inclusion Criteria

Patients older than 16 years old who have one of the following factors and stay in ICU for 5 days.
Subarachnoid Hemorrhage
Subdural Hematoma
Traumatic brain injury
Aneurysm
Intracranial hemorrhage
Others

Exclusion Criteria

Patient's death during the first three days of study
Patient dis-admit with personal satisfaction within the first three days
Disapprove of the patient to enter the research
Contraindication of receiving high protein die
Hepatic encephalopathy
An allergy to the drug
Consumer of Warfarin
Pregnancy
Metabolic disorders (gout, phenylketonuria)
Chronic renal failure
Proteinuria is higher than 3 grams per day

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
euron Specific Enolase. Timepoint: At the beginning of the intervention (before the intervention) and 3 and 5 days after the beginning of the intervention. Method of measurement: Enolase CanAg kit.;Serum Transtreatin Level. Timepoint: At the beginning of the intervention (before the intervention) and 3 and 5 days after the beginning of the intervention. Method of measurement: Prealbumin Minineph *25T.;Nitrogen Balance. Timepoint: At the beginning of the intervention (before the intervention) and 5 days after the beginning of the intervention. Method of measurement: Based on urea concentration.

Secondary Outcome Measures

Name	Time	Method
Extended Glasgow Outcome Scale. Timepoint: The end of the first, second and third months after the begining intervention. Method of measurement: Score of Extended Glasgow Outcome Scale.;Mortality. Timepoint: The end of the first, second and third months after the begining intervention. Method of measurement: Will be checked by phone.;Effect of medication on neuron specific Enolase. Timepoint: At the beginning of the intervention (before the intervention) and 3 and 5 days after the beginning of the intervention. Method of measurement: Blood sample.;Effect of medication on serum prealbumin level. Timepoint: At the beginning of the intervention (before the intervention) and 3 and 5 days after the beginning of the intervention. Method of measurement: blood sample.;Effect of medication on nitrogen balance. Timepoint: At the beginning of the intervention (before the intervention) and 5 days after the beginning of the intervention. Method of measurement: Urine sample.